Drug Trial Radar · NCT06846099
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Dec 7, 2022
Primary completion
May 30, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib).
Conditions
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Breast Cancer
- Solid Tumor Cancer
Interventions
RP903Drug
Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle; Ib: RP903,RP2D,po qd for each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ia:dose-limiting toxicity(DLTs)Time frame: 28 days
- Ia:Adverse EventsTime frame: 2 years
- Ia: serious adverse eventsTime frame: 2 years
- Ia: Abnormal changes in Laboratory test and other abnormalitiesTime frame: 2 years
- Ia: MTDTime frame: 2 years
- Ia: MADTime frame: 2 years
- Ia:RP2DTime frame: 2 years
- Ib:objective response rate(ORR);Time frame: 2 years
- Ib:AETime frame: 2 years
- Ib:SAETime frame: 2 years
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Jilin Cancer Hospital
Changchun, China
Jilin University First Hospital
Changchun, China
Sichuan Cancer Hospital
Chengdu, China
Chongqing University Cancer Hospital
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Fujian Medical University Union Hospital
Fuzhou, China
Sir Run Run Shaw Hospital
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shandong Cancer Hospital & Institute
Jinan, China
Affiliated Hospital of Jining Medical College
Jining, China
Linyi Cancer Hospital
Linyi, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
Guangxi Medical University Cancer Hospital
Nanning, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Affiliated Cancer Hospital of Fudan University
Shanghai, China
Liaoning Cancer Hospital&Institute
Shenyang, China
Suining Central Hospital
Suining, China
Hubei Cancer Hospital
Wuhan, China
Ceneral Hosipital of Ningxia Medical University
Yinchuan, China
Henan Cancer Hospital
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.